Quantitative Investment Management LLC bought a new position in shares of Radius Health, Inc. (NASDAQ:RDUS) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 17,800 shares of the biopharmaceutical company’s stock, valued at approximately $805,000.

Other large investors have also modified their holdings of the company. BlackRock Inc. lifted its position in shares of Radius Health by 98,245.6% in the 1st quarter. BlackRock Inc. now owns 2,630,745 shares of the biopharmaceutical company’s stock worth $101,679,000 after buying an additional 2,628,070 shares during the last quarter. TimesSquare Capital Management LLC acquired a new position in shares of Radius Health in the 2nd quarter valued at about $25,589,000. Credit Agricole S A acquired a new position in shares of Radius Health in the 1st quarter valued at about $10,026,000. Bank of New York Mellon Corp boosted its holdings in shares of Radius Health by 67.8% in the 1st quarter. Bank of New York Mellon Corp now owns 444,049 shares of the biopharmaceutical company’s stock valued at $17,163,000 after buying an additional 179,471 shares during the period. Finally, Capital Fund Management S.A. boosted its holdings in shares of Radius Health by 307.6% in the 2nd quarter. Capital Fund Management S.A. now owns 148,809 shares of the biopharmaceutical company’s stock valued at $6,731,000 after buying an additional 112,300 shares during the period.

TRADEMARK VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this article can be accessed at https://www.watchlistnews.com/17800-shares-in-radius-health-inc-rdus-purchased-by-quantitative-investment-management-llc/1602596.html.

Radius Health, Inc. (NASDAQ RDUS) opened at 38.55 on Monday. Radius Health, Inc. has a 52-week low of $31.58 and a 52-week high of $55.97. The company’s market cap is $1.68 billion. The stock’s 50 day moving average is $36.80 and its 200 day moving average is $38.96.

Radius Health (NASDAQ:RDUS) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.35) by ($0.23). The firm had revenue of $0.98 million during the quarter, compared to analyst estimates of $1.96 million. During the same period in the previous year, the firm posted ($1.01) earnings per share. On average, analysts predict that Radius Health, Inc. will post ($5.58) earnings per share for the current fiscal year.

In other news, major shareholder Growth N. V. Biotech purchased 150,000 shares of the business’s stock in a transaction that occurred on Thursday, August 10th. The stock was purchased at an average cost of $34.97 per share, with a total value of $5,245,500.00. Following the acquisition, the insider now directly owns 5,113,799 shares of the company’s stock, valued at approximately $178,829,551.03. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Growth N. V. Biotech purchased 60,000 shares of Radius Health stock in a transaction on Wednesday, August 16th. The stock was purchased at an average price of $35.98 per share, for a total transaction of $2,158,800.00. Following the completion of the transaction, the insider now owns 5,248,799 shares of the company’s stock, valued at $188,851,788.02. The disclosure for this purchase can be found here. Insiders have acquired 469,100 shares of company stock valued at $16,328,382 over the last quarter. Corporate insiders own 15.00% of the company’s stock.

A number of equities research analysts recently weighed in on RDUS shares. Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research report on Friday. They noted that the move was a valuation call. Canaccord Genuity set a $85.00 target price on shares of Radius Health and gave the stock a “buy” rating in a report on Monday, July 17th. BidaskClub cut shares of Radius Health from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Cantor Fitzgerald set a $65.00 target price on Radius Health and gave the company a “buy” rating in a research note on Monday, July 17th. Finally, Jefferies Group LLC restated a “hold” rating and issued a $38.00 target price (up from $34.00) on shares of Radius Health in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The company has an average rating of “Hold” and an average target price of $53.60.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Institutional Ownership by Quarter for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.